Canagliflozin and Rifampin Interaction
Drug interaction information between Canagliflozin and Rifampin.
Canagliflozin and Rifampin have a documented moderate interaction in FDA labeling.
FDA drug labeling documents a moderate-severity interaction between Canagliflozin and Rifampin. Major interactions are generally avoided, moderate ones may need monitoring or a dose adjustment, and minor ones are usually low-risk. This page shows the documented mechanism and guidance. Label-documented interactions are not a complete safety review, so always confirm your own medications with a pharmacist or doctor. Educational information, not medical advice.
How They Interact
Rifampin causes your body to process and remove the diabetes medicine more quickly than usual. This can make the diabetes medicine less effective at lowering your blood sugar.
What To Do
Your doctor may need to check your blood sugar levels more often. They might need to increase your dose of the diabetes medicine while you are taking rifampin.
FDA Label Information
Examples: Rifampin, phenytoin, phenobarbital, ritonavir Insulin or Insulin Secretagogues Clinical Impact: The risk of hypoglycemia is increased when INVOKANA is used concomitantly with insulin secretagogues (e.g., sulfonylurea) or insulin.
Canagliflozin Also Interacts With
- Phenytoin moderate
- Phenobarbital moderate
- Lithium minor
- Digoxin minor
Rifampin Also Interacts With
- Darunavir major
- Bictegravir/Emtricitabine/Tenofovir major
- Glecaprevir/Pibrentasvir major
- Nirmatrelvir/Ritonavir major
- Pitavastatin major
Frequently Asked Questions
Can I take Canagliflozin and Rifampin together?
This is a moderate interaction. Your doctor may need to check your blood sugar levels more often. They might need to increase your dose of the diabetes medicine while you are taking rifampin.
How serious is the interaction between Canagliflozin and Rifampin?
This interaction is classified as "moderate" severity by the FDA. Moderate interactions may worsen your condition or change how your medications work.
Why do Canagliflozin and Rifampin interact?
Rifampin causes your body to process and remove the diabetes medicine more quickly than usual. This can make the diabetes medicine less effective at lowering your blood sugar.
Understanding the Canagliflozin and Rifampin Interaction
FDA-approved prescribing information for these two drugs flags their combination as a moderate-severity interaction. Canagliflozin belongs to the SGLT2 Inhibitor class and Rifampin belongs to the Rifamycin Antibiotic class - two categories that can collide when co-prescribed. The mechanism described in FDA labeling is: Rifampin causes your body to process and remove the diabetes medicine more quickly than usual. Severity tiers matter: major flags generally advise avoidance, moderate flags often require monitoring or dose adjustment, and minor flags may only call for awareness.
Context around a specific patient determines real-world impact. Canagliflozin has 5 total documented interactions on file in this dataset, and Rifampin has 137. Each additional medication compounds the interaction surface, which is why pharmacists run full-profile checks rather than evaluating one pair at a time. FDA-derived guidance for this pair is: Your doctor may need to check your blood sugar levels more often. Timing of doses, renal and hepatic function, age, and other concurrent prescriptions all shape whether a labeled interaction matters clinically.
An interaction flag is not a verdict. A large share of labeled interactions are managed routinely in clinical practice, the fix may be as simple as spacing doses or adding a monitoring test. Others require the prescriber to choose a different medication entirely. This page surfaces FDA-sourced labeling and openFDA data for educational purposes only; it is not medical advice and cannot account for your full clinical picture. Never start, stop, or adjust either Canagliflozin or Rifampin based on a web page, speak with your prescriber or pharmacist before making any change.
Sources: FDA Drug Labels (SPL) via openFDA (2026). This is for informational purposes only and is not medical advice. Always consult your healthcare provider about drug interactions.
Read our methodology - how this data is sourced, computed, and verified.